Navigation Links
TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
Date:10/10/2008

PLEASANTON, Calif., Oct. 10 /PRNewswire/ -- TriReme Medical Inc. (TMI) announced today that it has been authorized to affix the CE (Conformite Europeenne) marking and commercialize in Europe the Antares(TM) Coronary Stent System, a unique main vessel stent system specially designed for use at or near coronary bifurcations.

Representing the next generation in bifurcation stenting, the Antares(TM) system has potential use in a quarter of the 2.2 million angioplasty procedures performed annually worldwide. Antares(TM) stents are not yet approved in the United States and are limited by Federal law to investigational use.

"We are very pleased to achieve this significant milestone that allows commercialization of our Antares(TM) stent system in Europe," said Eitan Konstantino, PhD, President and Chief Executive Officer of TMI. "We believe that the Antares(TM) stent system represents a breakthrough in the treatment of patients suffering from coronary artery disease at or near bifurcations.

"I like the Antares(TM) system concept. The system is designed to fit all classes of bifurcation lesions, irrespective of the size and angulation of the side-branch," said Professor Carlo Di Mario from Royal Brompton Hospital in London. "The operator does not need to commit to a pre-determined side branch treatment and has the flexibility to do what is right for the patient."

Lesions at or near side branches in the coronary tree pose multiple challenges to interventional cardiologists. Combining a low profile stent with a proprietary delivery system, the Antares(TM) system provides a unique set of solutions to the challenges of bifurcation stenting. It can be delivered and deployed in a single step while maintaining access to the side branch and scaffolding the ostium, or the origin of the side branch. As a result, the cardiologist has greater flexibility of treatment options, with the freedom to deploy a second stent in the side branch when additional
'/>"/>

SOURCE TriReme Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015  Semler Scientific, Inc. (Nasdaq: SMLR ), ... healthcare insurers and physician groups, today reported financial results ... "In the second quarter of 2015, Semler ... of 54%, quarter over quarter revenue growth of 8%, ... of FloChec® units of 18%," said Doug Murphy-Chutorian, M.D., ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015  Eisai ... Ltd. (Headquarters: Tokyo , President and ... Inc. (Headquarters: San Diego, California , ... HALO") have signed a clinical collaboration agreement to evaluate ... in combination with Halozyme,s investigational drug PEGPH20 (PEGylated recombinant ...
(Date:7/31/2015)... , July 31, 2015  Xencor, Inc. (NASDAQ: ... antibodies for the treatment of autoimmune diseases, asthma and ... Yujiro S. Hata to its board of ... business and corporate development is a tremendous asset to ... and chief executive officer of Xencor. "Xencor faces a ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... - the novel,selective relaxant binding agent (SRBA) being ... Akzo Nobel - demonstrated in,a Phase III pivotal ... as compared to neostigmine, without evidence,of post operative ... The results of this pivotal Aurora trial,were presented ...
... 11, 2007 (MARKET WIRE via COMTEX News,Network) ... target=,"_blank" href="http://www.myriad.com/">www.myriad.com ),announced today that it presented ... a "Randomized Withdrawal" clinical trial,design with a ... the Alzheimer's Association Prevention Conference held,June 9 ...
Cached Medicine Technology:Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial Compared to Neostigmine 2Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial Compared to Neostigmine 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 2Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 4Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 5
(Date:7/31/2015)... , ... July 31, 2015 , ... ... announced plans to release a newly redesigned website at Healthpointe.net. The new website ... user experience. , The redesign serves to provide smoother interactions between patients ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Women's ... Center for Natural Birth . The Karmanos Center for Natural Birth provides ... experience. With nurses and caregivers that are trained in holistic birth approaches, patients ...
(Date:7/31/2015)... ... July 31, 2015 , ... A ... natural, therapeutic-grade oils from ingredients sourced all over the world, then manufactured into ... effort, we have developed the highest-quality oils in the industry, which we are ...
(Date:7/31/2015)... ... July 31, 2015 , ... Super-Sod wants to participate in planning new home ... as the perfect fit for such a goal. Houzz is a social media ... is a dynamic site that spreads home and home garden design ideas when members ...
(Date:7/31/2015)... Orlando, FL (PRWEB) , ... July 31, 2015 , ... ... visiting the United States for temporary work, study or family visit for the past ... in their 80s and 90s are able to travel and spend time with their ...
Breaking Medicine News(10 mins):Health News:Healthpointe Announces Newly Redesigned Website 2Health News:Living Pure Essential Oils takes Therepeutic Essential Oil Market by Storm 2Health News:Super-Sod Created a Landscape Profile on Houzz.com for Home Garden Design 2Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 2Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 3
... growing brain tumors must adjust to periods of low ... cells grow and proliferate. When levels are low, the ... Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer ... the switch responsible for this grow-or-go behavior. , Their ...
... that the company received Registration Certificate for its MEVAC-Vari vaccine in Guatemala . , ... , , ... ... ...
... author, and lecturer Dr. William Sears and his product team have announced the launch of ... Expo West convention to be held in Anaheim, CA March 12-14 . The company,s ... ... ...
... ... and food security has wide-ranging benefits compared to its costs in the fight against ... Congressional hearing on global hunger. He cites findings from Nobel laureates and a Lancet ... ...
... ... ... 11, 2010 -- Qualifacts Systems Inc. , the largest Software as a Service ... and human services providers, has added New Directions Inc. to its client roster – ...
... ... President of International Orion Health – Charles Scatchard. Orion Health celebrates “phenomenal success” with ... , ... (PRWEB) March 12, 2010 -- To further the ongoing success with implementing Healthcare IT ...
Cached Medicine News:Health News:Researchers discover brain tumor's 'grow-or-go' switch 2Health News:Researchers discover brain tumor's 'grow-or-go' switch 3Health News:Hard to Treat Diseases (HTDS) Acquired Varicella Approval in Guatemala 2Health News:Hard to Treat Diseases (HTDS) Acquired Varicella Approval in Guatemala 3Health News:Hard to Treat Diseases (HTDS) Acquired Varicella Approval in Guatemala 4Health News:Hard to Treat Diseases (HTDS) Acquired Varicella Approval in Guatemala 5Health News:America's Pediatrician Dr. Bill Sears Answers Michelle Obama's Call to Action to Help Eradicate Obesity 2Health News:America's Pediatrician Dr. Bill Sears Answers Michelle Obama's Call to Action to Help Eradicate Obesity 3Health News:Nutritional Aid is Cost-effective Measure Against Health and Hunger Problems, World Vision Tells Congress 2Health News:Nutritional Aid is Cost-effective Measure Against Health and Hunger Problems, World Vision Tells Congress 3Health News:Qualifacts is Behavioral Health SaaS Provider of Choice in Connecticut 2Health News:Orion Health Showcases Industry Leading EHR Software at WoHIT 2Health News:Orion Health Showcases Industry Leading EHR Software at WoHIT 3Health News:Orion Health Showcases Industry Leading EHR Software at WoHIT 4Health News:Orion Health Showcases Industry Leading EHR Software at WoHIT 5
PremierEdge™ Stab Knives - 45°....
PremierEdge Stab Knives - 15....
More Info Lacrimal Intubation Set. Size: Probes 23g x 7"....
... use of the Leica CM1900 as well ... the instrument of choice in many routine ... open top stainless steel cryochamber with separate ... ample space for convenient working and storage ...
Medicine Products: